Xbrane Biopharma AB (publ) ("Xbrane" or "the Company”) represented by Martin Åmark, CEO, presents at the Småbolagsdagen February 24, 2021. Follow the presentation of Xbrane’s development focusing on the up-coming draft read-out from the phase III data for the biosimilarcandidate Xlucane and the planned application for market authorization.
Time: February 24, kl. 08.00 – 13.10
Time and weblink to Xbrane´s presentation: kl 10.40, https://tv.streamfabriken.com/2021-02-24-xbrane-biopharma
The Småbolagsdagen is a collaboration between Financial Hearings and Börsveckan. The companies present their operations and afterwards follows a question-and-answer session led by Lars Frick, an analyst at Börsveckan.